Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lehrke

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
Nature Medicine|February 5, 2004
Inflamed about obesityMichael Lehrke, Mitchell A Lazar
Cell|December 20, 2005
The many faces of PPARgammaMichael Lehrke, Mitchell A Lazar
The Journal of Thoracic and Cardiovascular Surgery|April 4, 2021
Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?Pascal Alexander Mann, Michael Lehrke
Pharmacogenomics|April 23, 2002
Novel insulin sensitizers: pharmacogenomic aspectsCarsten Otto, Michael Lehrke, Burkhard Göke
Circulation Research|April 13, 2023
The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and TherapyKatharina Schuett, Nikolaus Marx, Michael Lehrke
MMW Fortschritte Der Medizin|March 9, 2023
[Indications of antidiabetic drugs beyond glucose control]Niels-Ulrik Korbinian Hartmann, Michael Lehrke
Metabolism: Clinical and Experimental|December 11, 2019
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failureFrancesco Giorgino, Irene Caruso, Julia Moellmann, et al.
Nature Reviews. Nephrology|May 11, 2021
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterationsHeidi Noels, Michael Lehrke, Raymond Vanholder, et al.
Molecular Aspects of Medicine|February 27, 2022
Glucose-derived posttranslational modification in cardiovascular diseaseMichael Lehrke, Julia Moellmann, Florian Kahles, et al.
Frontiers in Immunology|December 5, 2015
High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting MechanismsKatharina Andrea Schuett, Michael Lehrke, Nikolaus Marx, et al.
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
Nature Medicine|February 5, 2004
Inflamed about obesityMichael Lehrke, Mitchell A Lazar
Cell|December 20, 2005
The many faces of PPARgammaMichael Lehrke, Mitchell A Lazar
The Journal of Thoracic and Cardiovascular Surgery|April 4, 2021
Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?Pascal Alexander Mann, Michael Lehrke
Pharmacogenomics|April 23, 2002
Novel insulin sensitizers: pharmacogenomic aspectsCarsten Otto, Michael Lehrke, Burkhard Göke
Circulation Research|April 13, 2023
The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and TherapyKatharina Schuett, Nikolaus Marx, Michael Lehrke
MMW Fortschritte Der Medizin|March 9, 2023
[Indications of antidiabetic drugs beyond glucose control]Niels-Ulrik Korbinian Hartmann, Michael Lehrke
Metabolism: Clinical and Experimental|December 11, 2019
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failureFrancesco Giorgino, Irene Caruso, Julia Moellmann, et al.
Nature Reviews. Nephrology|May 11, 2021
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterationsHeidi Noels, Michael Lehrke, Raymond Vanholder, et al.
Molecular Aspects of Medicine|February 27, 2022
Glucose-derived posttranslational modification in cardiovascular diseaseMichael Lehrke, Julia Moellmann, Florian Kahles, et al.
Frontiers in Immunology|December 5, 2015
High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting MechanismsKatharina Andrea Schuett, Michael Lehrke, Nikolaus Marx, et al.
Pageof 13